Journal of Clinical Oncology, Vol 5, 55-61, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients

GM Clark, GW Sledge Jr, CK Osborne and WL McGuire

Univariate and multivariate analyses of potential prognostic factors for 1,015 women with recurrent breast cancer confirmed that the site of initial recurrence is an important determinant for predicting survival from the time of initial recurrence. However, both estrogen receptor (ER) status and axillary lymph node status at diagnosis, as well as the length of the disease-free interval, provide additional independent information for predicting patient survival after disease recurrence. Involved axillary lymph nodes at the time of initial diagnosis and/or lack of ERs may indicate a highly malignant tumor or a weak host defense, either of which might be related to short survival after relapse. Patients with ER-negative tumors recurred more often in visceral and soft-tissue sites, while patients with ER-positive tumors were more likely to recur in bony sites. However, for each metastatic site, receptor-positive patients had longer survival

This article has been cited by other articles:

				D. Palmieri, J. L. Bronder, J. M. Herring, T. Yoneda, R. J. Weil, A. M. Stark, R. Kurek, E. Vega-Valle, L. Feigenbaum, D. Halverson, et al. Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain Cancer Res., May 1, 2007; 67(9): 4190 - 4198. [Abstract] [Full Text] [PDF]

				N. Kroger, M. Frick, O. Gluz, S. Mohrmann, B. Metzner, C. Jackisch, Y. Ko, H.-W. Lindemann, C. R. Meier, H. P. Lohrmann, et al. Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer J. Clin. Oncol., August 20, 2006; 24(24): 3919 - 3926. [Abstract] [Full Text] [PDF]

				J. B Engel, A. V Schally, G. Halmos, B. Baker, A. Nagy, and G. Keller Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins Endocr. Relat. Cancer, December 1, 2005; 12(4): 999 - 1009. [Abstract] [Full Text] [PDF]

				H. J. Burstein, G. Lieberman, D. J. Slamon, E. P. Winer, and P. Klein Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy Ann. Onc., November 1, 2005; 16(11): 1772 - 1777. [Abstract] [Full Text] [PDF]

				R. J. Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg Breast Cancer Metastasis to the Central Nervous System Am. J. Pathol., October 1, 2005; 167(4): 913 - 920. [Abstract] [Full Text] [PDF]

				R. J. Bennink, G. van Tienhoven, L. J. Rijks, A. L. Noorduyn, A. G. Janssen, and G. W. Sloof In Vivo Prediction of Response to Antiestrogen Treatment in Estrogen Receptor-Positive Breast Cancer J. Nucl. Med., January 1, 2004; 45(1): 1 - 7. [Abstract] [Full Text] [PDF]

				S. Tsutsui, A. Kataoka, S. Ohno, S. Murakami, J. Kinoshita, and Y. Hachitanda Prognostic and Predictive Value of Epidermal Growth Factor Receptor in Recurrent Breast Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3454 - 3460. [Abstract] [Full Text] [PDF]

				R. J. Bennink, L. J. Rijks, G. van Tienhoven, L. A. Noorduyn, A. G. Janssen, and G. W. Sloof Estrogen Receptor Status in Primary Breast Cancer: Iodine 123-labeled cis-11{beta}-Methoxy-17{alpha}-iodovinyl Estradiol Scintigraphy Radiology, September 1, 2001; 220(3): 774 - 779. [Abstract] [Full Text] [PDF]

				M. Extermann, L. Balducci, and G. H. Lyman What Threshold for Adjuvant Therapy in Older Breast Cancer Patients? J. Clin. Oncol., April 1, 2000; 18(8): 1709 - 1717. [Abstract] [Full Text] [PDF]

				B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1378 - 1391. [Abstract] [Full Text] [PDF]

				J. Alexandre, P. Bleuzen, J. Bonneterre, W. Sutherland, J. L. Misset, J.-P. Guastalla, P. Viens, S. Faivre, A. Chahine, M. Spielman, et al. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients J. Clin. Oncol., February 1, 2000; 18(3): 562 - 562. [Abstract] [Full Text] [PDF]

				K. H. Antman, D. F. Heitjan, and G. N. Hortobagyi High-Dose Chemotherapy for Breast Cancer JAMA, November 10, 1999; 282(18): 1701 - 1703. [Full Text] [PDF]

				I. Jatoi, S. G. Hilsenbeck, G. M. Clark, and C. K. Osborne Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer J. Clin. Oncol., August 1, 1999; 17(8): 2334 - 2334. [Abstract] [Full Text] [PDF]